Observational studyNature communications2026
Plasma autoantibody profiling via PhIP-seq and machine learning for diagnosis of esophageal squamous cell carcinoma.
Observational study in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of esophageal squamous cell carcinoma (ESCC) is crucial for improving patient survival. This study employed phage immunoprecipitation sequencing (PhIP-Seq) to comprehensively profile circulating autoantibodies using 1039 plasma samples from a multicenter cohort. Through integrated machine learning approaches, we identified a panel of core antigenic peptides that effectively distinguish ESCC patients from normal controls. The established diagnostic model, based on XGBoost and featuring autoantibodies against antigens such as KMT2C and INPP4B, demonstrated robust performance across multiple validation sets. It achieved area under the curve (AUC) values of 0.912 (95% CI: 0.878-0.946) in the training set, 0.782 (95% CI: 0.696-0.868) in the internal validation set, 0.809 (95% CI: 0.762-0.856) and 0.729 (95% CI: 0.570-0.889) in two independent external cohorts, respectively. Furthermore, the model showed preliminary potential in assessing treatment response, suggesting its possible utility in disease monitoring, although this finding requires independent validation in larger prospective cohorts. This work provides a framework for non-invasive ESCC detection and precision management.
Indexed as
Identifiers
42881190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.